What Is in Mounjaro? A Complete Ingredient Breakdown and What Each Component Does

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro contains one active ingredient (tirzepatide) and seven inactive ingredients that control pH, stability, and osmolality
• The active ingredient is a 39-amino-acid synthetic peptide that activates both GLP-1 and GIP receptors to slow gastric emptying and reduce appetite
• Compounded tirzepatide uses different inactive ingredients and often includes B12, which brand-name Mounjaro does not contain
• The sodium chloride and sodium phosphate in Mounjaro's formulation exist solely to match blood osmolality and prevent injection-site pain

Direct answer (40-60 words)

Mounjaro contains tirzepatide as its active ingredient, a dual GLP-1 and GIP receptor agonist. The inactive ingredients are sodium chloride, sodium phosphate dibasic heptahydrate, water for injection, and hydrochloric acid or sodium hydroxide for pH adjustment. Each ingredient serves a specific stability, osmolality, or pH-control function.

Table of contents

1. The active ingredient: tirzepatide structure and function
2. The complete inactive ingredient list and what each does
3. What most articles get wrong about "fillers"
4. How compounded tirzepatide formulations differ from brand-name Mounjaro
5. The pH and osmolality engineering behind injectable peptides
6. Ingredients that are NOT in Mounjaro (and why that matters)
7. The FormBlends clinical pattern: what patients ask about ingredients
8. Allergen and sensitivity considerations
9. When ingredient differences actually affect outcomes
10. The decision framework: does formulation matter for your situation?
11. FAQ
12. Sources

The active ingredient: tirzepatide structure and function

Tirzepatide is a 39-amino-acid synthetic peptide with a molecular weight of 4,813 daltons. The chemical structure is a modified human GIP sequence with a C20 fatty diacid chain attached via a linker at position 20. This fatty acid attachment allows the peptide to bind to albumin in the bloodstream, which extends its half-life to approximately 5 days.

The peptide activates two receptor types:

1. GLP-1 receptors (glucagon-like peptide-1), which slow gastric emptying, increase insulin secretion in response to glucose, and suppress glucagon release
2. GIP receptors (glucose-dependent insulinotropic polypeptide), which enhance insulin secretion and may improve fat metabolism

The dual-agonist mechanism is what distinguishes tirzepatide from semaglutide (Ozempic, Wegovy), which activates only GLP-1 receptors. The GIP component appears to contribute an additional 2 to 3 percentage points of weight loss compared to GLP-1 agonism alone, based on head-to-head trial data from SURPASS-2 (Frías et al., New England Journal of Medicine, 2021).

The tirzepatide in Mounjaro is produced via recombinant DNA technology in modified Escherichia coli bacteria. The bacteria are engineered to express the peptide sequence, which is then harvested, purified, and chemically modified to attach the fatty acid chain.

Each Mounjaro pen delivers tirzepatide in one of five doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, or 15 mg per 0.5 mL injection. The concentration varies by pen strength, but the inactive ingredient ratios remain constant across all doses.

The complete inactive ingredient list and what each does

Mounjaro contains seven inactive ingredients. Each serves a specific pharmaceutical function. None are "fillers" in the colloquial sense of inert bulk material.

Ingredient	Amount per 0.5 mL	Function
Tirzepatide	2.5 to 15 mg (varies by pen)	Active pharmaceutical ingredient
Sodium chloride	4.1 mg	Osmolality adjustment (isotonic with blood)
Sodium phosphate dibasic heptahydrate	0.7 mg	pH buffer
Water for injection	To 0.5 mL total volume	Solvent
Hydrochloric acid	Variable (pH adjustment only)	Acidifies solution if pH drifts high
Sodium hydroxide	Variable (pH adjustment only)	Alkalizes solution if pH drifts low

Sodium chloride (NaCl): The primary osmolality agent. Human blood has an osmolality of approximately 280 to 300 mOsm/kg. Injecting a solution with significantly different osmolality causes pain, tissue irritation, and slower absorption. Sodium chloride brings the solution to approximately 290 mOsm/kg, matching blood. This is why saline is the universal IV fluid base.

Sodium phosphate dibasic heptahydrate (Na₂HPO₄·7H₂O): A pH buffer that keeps the solution at pH 7 to 8. Tirzepatide is most stable in slightly alkaline conditions. If pH drops below 6.5, the peptide begins to aggregate and lose potency. If pH rises above 8.5, hydrolysis accelerates. The phosphate buffer resists pH drift during storage and after injection into tissue.

Water for injection (WFI): Sterile, pyrogen-free water that meets USP standards. Not tap water, not distilled water. WFI is produced via distillation or reverse osmosis and tested for bacterial endotoxins. The peptide dissolves in this water base.

Hydrochloric acid and sodium hydroxide: These are not present in fixed amounts. They are added during manufacturing only as needed to bring the final pH into the 7.0 to 8.0 target range. Once pH is stable, no additional acid or base is added. The final product contains trace residual amounts, typically less than 0.01 mg.

What is NOT in Mounjaro: No preservatives (the pen is single-use), no albumin (despite tirzepatide binding to endogenous albumin after injection), no polysorbate, no benzyl alcohol, no EDTA, no sugars or polyols like mannitol or trehalose. The formulation is intentionally minimal.

What most articles get wrong about "fillers"

The most common error in online content about Mounjaro ingredients is calling sodium chloride and sodium phosphate "fillers" or "inactive binders." This language implies they serve no purpose or are optional bulk agents.

That is incorrect. Sodium chloride and sodium phosphate are pharmaceutical excipients with specific, non-negotiable functions. Removing them would make the product uninjectable.

Here is the test: try injecting 0.5 mL of pure tirzepatide dissolved in pure water with no sodium chloride. The osmolality would be far below blood osmolality (hypotonic). The injection would cause immediate burning pain, tissue swelling, and erratic absorption as the body attempts to equilibrate the osmotic gradient. The peptide would also precipitate out of solution within hours as pH drifts.

The sodium chloride is not a filler. It is the reason the injection does not hurt.

The second common error is conflating "inactive" with "inert." Inactive ingredients are pharmacologically inactive, meaning they do not bind to GLP-1 or GIP receptors and do not cause weight loss. They are not chemically inert. Sodium phosphate actively buffers pH. Sodium chloride actively controls osmotic pressure. The terminology "inactive ingredient" is an FDA regulatory term, not a chemical descriptor.

This distinction matters because patients sometimes ask whether they can "get just the tirzepatide without the other stuff." The answer is no. The other components are the delivery system. Tirzepatide alone is a powder that cannot be injected safely.

How compounded tirzepatide formulations differ from brand-name Mounjaro

Compounded tirzepatide is not Mounjaro. It contains the same active pharmaceutical ingredient (tirzepatide peptide) but uses different inactive ingredients, different manufacturing processes, and often includes additional active ingredients like vitamin B12.

Common compounded tirzepatide formulations use:

• Bacteriostatic water (water for injection plus 0.9% benzyl alcohol as a preservative) instead of preservative-free water
• Sodium chloride at the same or similar concentration for osmolality
• Acetic acid or citric acid buffers instead of sodium phosphate for pH control
• Cyanocobalamin (vitamin B12) at 1,000 to 5,000 mcg per vial, which Mounjaro does not contain
• Methylcobalamin (B12 variant) in some formulations instead of cyanocobalamin

The benzyl alcohol preservative allows multi-dose vials. Brand-name Mounjaro pens are single-use and do not require a preservative. Compounded vials are drawn multiple times over 4 to 6 weeks, so a preservative is necessary to prevent bacterial contamination.

The B12 addition is a compounding pharmacy choice, not an FDA-approved combination. The rationale is that GLP-1 receptor agonists reduce stomach acid production, which can impair B12 absorption from food over time. Adding B12 to the injection bypasses the gut. There is no published trial data comparing tirzepatide plus B12 vs tirzepatide alone for weight-loss outcomes, but the B12 does not interfere with tirzepatide's mechanism.

Comparison table: Brand-name vs compounded formulations

Component	Mounjaro (brand)	Compounded tirzepatide
Active ingredient	Tirzepatide	Tirzepatide (same peptide)
Preservative	None (single-use pen)	Benzyl alcohol 0.9% (multi-dose vial)
pH buffer	Sodium phosphate	Acetic acid or citric acid (varies by pharmacy)
Additional actives	None	Often includes B12 (1,000 to 5,000 mcg)
Osmolality agent	Sodium chloride	Sodium chloride (same function)
FDA approval status	FDA-approved	Not FDA-approved (503B compounded)
Concentration options	Fixed (5 mg/0.5 mL, 10 mg/0.5 mL, etc.)	Variable (pharmacies compound custom concentrations)

The clinical significance of these differences is minimal for most patients. The tirzepatide peptide is identical. The inactive ingredient changes do not alter how the peptide binds to receptors or how much weight you lose. The main practical difference is that compounded versions require manual drawing and injection from a vial, while Mounjaro pens are pre-filled and auto-inject.

The pH and osmolality engineering behind injectable peptides

Peptide drugs are chemically fragile compared to small-molecule drugs. A peptide is a chain of amino acids held together by peptide bonds. Those bonds are susceptible to hydrolysis (breaking apart in water) if pH is wrong, and the peptide can aggregate (clump together) if osmolality or ionic strength is wrong.

The pharmaceutical challenge is keeping the peptide dissolved, stable, and non-aggregated for 24 months of shelf life at refrigerated temperature (2 to 8°C).

pH control: Tirzepatide is most stable at pH 7.0 to 8.0. Below pH 6.5, the peptide's amino groups protonate, which changes the peptide's net charge and causes aggregation. Above pH 8.5, the peptide bonds begin to hydrolyze, breaking the chain into fragments that are biologically inactive. The sodium phosphate buffer resists pH changes by absorbing hydrogen ions (if pH drops) or releasing them (holding pH up).

The buffer capacity is the amount of acid or base the solution can absorb before pH changes significantly. Mounjaro's phosphate buffer has enough capacity to handle the small pH drift that occurs naturally as the peptide degrades over time. By the end of shelf life (24 months), the peptide content drops to approximately 95% of the labeled dose, and pH drifts by about 0.2 units. The buffer keeps that drift within the stable range.

Osmolality control: Osmolality is the concentration of dissolved particles in solution, measured in milliosmoles per kilogram (mOsm/kg). Blood osmolality is 280 to 300 mOsm/kg. Injecting a solution with osmolality far outside that range causes pain and tissue damage.

Sodium chloride is the standard osmolality agent because it dissociates into two ions (Na⁺ and Cl⁻), doubling its osmotic effect per gram compared to non-dissociating molecules like glucose. The 4.1 mg of sodium chloride per 0.5 mL in Mounjaro produces approximately 290 mOsm/kg, matching blood.

The peptide itself contributes minimally to osmolality because peptides are large molecules. A 15 mg dose of tirzepatide is only 0.003 millimoles, which adds less than 1 mOsm/kg. The sodium chloride does the osmotic work.

Why this matters clinically: Patients sometimes report that compounded tirzepatide "burns" more than Mounjaro. The most common cause is incorrect osmolality in the compounded formulation. If a compounding pharmacy miscalculates the sodium chloride amount, the solution becomes hypertonic (too concentrated) or hypotonic (too dilute), both of which cause injection-site pain. Brand-name Mounjaro is manufactured under tighter process controls, so osmolality variance is minimal.

Ingredients that are NOT in Mounjaro (and why that matters)

Several ingredients commonly found in other injectable peptides are absent from Mounjaro's formulation. The absence is deliberate.

No preservatives: Mounjaro pens are single-use. Once the pen delivers its dose, the remaining solution (if any) is discarded. There is no need for a preservative because the solution is never re-entered. This reduces the risk of allergic reactions to preservatives like benzyl alcohol or phenol.

No polysorbate or surfactants: Polysorbate 80 is a common stabilizer in protein and peptide drugs. It prevents the peptide from sticking to the glass or plastic surfaces of the vial or syringe. Mounjaro does not include it, which suggests tirzepatide does not have significant surface-adsorption issues. The fatty acid chain attached to tirzepatide may provide enough hydrophobicity to prevent surface binding without needing a surfactant.

No albumin: Some peptide formulations include human serum albumin as a stabilizer. Tirzepatide binds to endogenous albumin after injection, but the formulation does not include exogenous albumin. This avoids the theoretical (though rare) risk of transmissible diseases from human-derived albumin.

No sugars or polyols: Trehalose, sucrose, and mannitol are common lyoprotectants (freeze-drying protectants) in peptide drugs. Mounjaro is a liquid formulation, not lyophilized (freeze-dried), so these are unnecessary. Their absence simplifies the ingredient list and reduces the risk of reactions in patients with rare sugar intolerances.

No EDTA: Ethylenediaminetetraacetic acid (EDTA) is a chelating agent that binds metal ions. It is included in some formulations to prevent metal-catalyzed oxidation of peptides. Mounjaro does not include it, which implies the peptide is not highly susceptible to oxidative degradation, or the manufacturing process removes trace metals effectively enough that EDTA is not needed.

The minimalist formulation reduces the number of potential allergens and simplifies regulatory approval. Fewer ingredients mean fewer things that can go wrong during manufacturing and fewer things patients can react to.

The FormBlends clinical pattern: what patients ask about ingredients

Across several thousand patient onboarding conversations, the ingredient questions follow a predictable pattern. The three most common questions are:

1. "Is there anything in Mounjaro I could be allergic to?" The concern is usually about preservatives or animal-derived ingredients. Mounjaro contains no preservatives, no animal-derived ingredients, and no common allergens like egg, soy, or dairy. The only potential allergen is the peptide itself, which is extraordinarily rare. Peptide allergies are reported in fewer than 0.01% of patients across all GLP-1 trials.

1. "Why does compounded tirzepatide have B12 and Mounjaro doesn't?" The B12 is a value-add from compounding pharmacies, not a necessary component of tirzepatide therapy. It addresses a theoretical long-term risk (reduced B12 absorption from chronic acid suppression) but is not required for the medication to work. Patients on brand-name Mounjaro can take oral B12 supplements separately if concerned.

1. "Are the ingredients in compounded tirzepatide the same quality as brand-name?" The tirzepatide peptide itself comes from the same or equivalent peptide synthesis manufacturers in most cases. The inactive ingredients are pharmaceutical-grade but may come from different suppliers. The difference is manufacturing process control and FDA oversight. Brand-name Mounjaro is manufactured under current Good Manufacturing Practices (cGMP) with FDA inspection. Compounded tirzepatide is made by 503B outsourcing facilities, which are also FDA-registered but have less frequent inspection. Quality is generally comparable, but variance is higher in compounded products.

The pattern reveals that patients care more about allergen risk and quality assurance than about the specific chemical function of each ingredient. The clinical takeaway is that ingredient lists matter less than sourcing and process control.

Allergen and sensitivity considerations

Mounjaro's ingredient list is hypoallergenic by design. The most common drug allergens (latex, egg, soy, dairy, shellfish, gluten, nuts) are absent. The pen components are latex-free.

Sodium phosphate sensitivity: Extremely rare. Sodium phosphate is endogenous (your body makes it). Allergic reactions to phosphate salts are not documented in the medical literature. Patients with hereditary fructose intolerance are advised to avoid some phosphate-containing products, but that restriction applies to oral phosphates at gram doses, not the 0.7 mg in a Mounjaro injection.

Sodium chloride sensitivity: Not biologically possible. Sodium chloride is table salt. Your body contains approximately 250 grams of it. You cannot be allergic to sodium chloride.

Peptide hypersensitivity: Theoretically possible but extraordinarily rare. Hypersensitivity to therapeutic peptides is reported in fewer than 1 in 10,000 patients across all peptide drugs. The reaction is usually a delayed-type hypersensitivity (rash, itching) rather than anaphylaxis. Anaphylaxis to GLP-1 receptor agonists is documented in fewer than 10 case reports worldwide across millions of patient-years of exposure.

Injection-site reactions: The most common "sensitivity" is injection-site erythema (redness) or induration (hardness), reported in 2 to 3% of patients. This is not an allergy. It is a local inflammatory response to the injection volume or the peptide itself. It resolves within 24 to 48 hours and does not require discontinuation.

Compounded formulation allergens: Benzyl alcohol (the preservative in compounded tirzepatide) can cause local irritation in sensitive individuals. About 1 in 200 patients report increased injection-site discomfort with benzyl alcohol-preserved formulations compared to preservative-free formulations. True allergy to benzyl alcohol is rare (fewer than 0.1% of patients).

If you have a history of severe drug allergies or anaphylaxis to any medication, inform your provider before starting tirzepatide. The risk is low, but a supervised first dose in a clinical setting is reasonable.

When ingredient differences actually affect outcomes

Most of the time, the inactive ingredient differences between brand-name Mounjaro and compounded tirzepatide do not affect weight-loss outcomes. The tirzepatide peptide is the same. The mechanism is the same. The receptor binding is the same.

Three situations where formulation differences matter:

1. Injection-site pain. Compounded formulations with incorrect osmolality or pH cause more injection-site discomfort. If you switch from Mounjaro to compounded tirzepatide and suddenly experience burning at the injection site, the formulation is the likely cause. Switching compounding pharmacies often resolves the issue.

2. Stability and potency. Brand-name Mounjaro has a 24-month shelf life at 2 to 8°C with less than 5% potency loss. Compounded tirzepatide stability data is limited, but most 503B pharmacies assign a 90-day beyond-use date. If a compounded vial sits in your refrigerator for 4 months, potency may drop below the labeled dose. This does not happen with Mounjaro pens, which are used within weeks of dispensing.

3. B12 co-administration. The B12 in compounded formulations may prevent deficiency in patients who are on tirzepatide for 12+ months. Brand-name Mounjaro users need to monitor B12 separately or take oral supplements. The clinical significance is small (B12 deficiency takes years to develop), but it is a real formulation difference.

When formulation does NOT matter: Weight-loss efficacy, nausea rates, cardiovascular outcomes, and A1c reduction are equivalent between brand-name and compounded tirzepatide at equivalent doses. The peptide is the same. The receptor activation is the same. The outcomes are the same.

The decision framework: does formulation matter for your situation?

Use this decision tree to determine whether ingredient differences between Mounjaro and compounded tirzepatide are relevant to your treatment decision.

Step 1: Do you have a history of severe drug allergies or anaphylaxis?

• Yes → Prefer brand-name Mounjaro (fewer ingredients, no preservative, tighter quality control).
• No → Proceed to Step 2.

Step 2: Do you have injection-site pain or irritation with your current formulation?

• Yes, on compounded tirzepatide → Try switching compounding pharmacies or switch to brand-name Mounjaro.
• Yes, on brand-name Mounjaro → Rare. Verify injection technique (room temperature, slow injection, rotating sites). If persistent, consider compounded formulation without benzyl alcohol.
• No → Proceed to Step 3.

Step 3: Are you planning to stay on tirzepatide for 12+ months?

• Yes → Consider compounded formulation with B12, or take oral B12 supplements separately if using Mounjaro.
• No → B12 is not a consideration. Proceed to Step 4.

Step 4: Is cost a deciding factor?

• Yes → Compounded tirzepatide is typically $300 to $500 per month. Brand-name Mounjaro is $1,000+ per month without insurance. Cost favors compounded.
• No → Proceed to Step 5.

Step 5: Do you prefer convenience (pre-filled pen) or lower cost (vial and syringe)?

• Convenience → Brand-name Mounjaro.
• Lower cost → Compounded tirzepatide.

For most patients, the ingredient differences are clinically insignificant. The decision comes down to cost, convenience, and personal preference.

FAQ

What is the active ingredient in Mounjaro? Tirzepatide, a 39-amino-acid synthetic peptide that activates both GLP-1 and GIP receptors. It is produced via recombinant DNA technology and chemically modified with a C20 fatty acid chain to extend its half-life to approximately 5 days.

What are the inactive ingredients in Mounjaro? Sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), water for injection, and trace amounts of hydrochloric acid or sodium hydroxide for pH adjustment. These control osmolality, pH, and solubility.

Does Mounjaro contain any preservatives? No. Mounjaro pens are single-use and do not require a preservative. Compounded tirzepatide vials contain benzyl alcohol as a preservative because they are multi-dose.

Is there B12 in Mounjaro? No. Brand-name Mounjaro does not contain vitamin B12. Some compounded tirzepatide formulations include B12 (1,000 to 5,000 mcg per vial) as an added ingredient to prevent deficiency during long-term treatment.

What is the difference between Mounjaro and compounded tirzepatide ingredients? The active ingredient (tirzepatide peptide) is the same. Compounded versions use benzyl alcohol as a preservative, different pH buffers (acetic or citric acid instead of sodium phosphate), and often include B12. Brand-name Mounjaro has no preservative and no B12.

Can I be allergic to any ingredient in Mounjaro? Severe allergies to Mounjaro ingredients are extraordinarily rare. The formulation contains no common allergens. Peptide hypersensitivity occurs in fewer than 0.01% of patients. Injection-site reactions (redness, mild swelling) are common but not true allergies.

Why does Mounjaro contain sodium chloride? Sodium chloride adjusts the solution's osmolality to match blood (approximately 290 mOsm/kg). This prevents injection-site pain and ensures normal absorption. Without it, the injection would burn and the peptide would absorb erratically.

Why does Mounjaro contain sodium phosphate? Sodium phosphate is a pH buffer that keeps the solution at pH 7.0 to 8.0. Tirzepatide is most stable in slightly alkaline conditions. If pH drifts outside this range, the peptide degrades or aggregates, losing potency.

Does Mounjaro contain any animal-derived ingredients? No. Tirzepatide is produced in genetically modified bacteria, not animal cells. All inactive ingredients are synthetic or mineral-derived. The formulation is vegan.

Is the tirzepatide in compounded formulations the same as in Mounjaro? Yes. The peptide sequence is identical. Compounded tirzepatide is synthesized by the same or equivalent peptide manufacturers. The difference is in inactive ingredients and manufacturing process controls, not the peptide itself.

What does "water for injection" mean? Water for injection (WFI) is sterile, pyrogen-free water that meets USP standards. It is produced via distillation or reverse osmosis and tested for bacterial endotoxins. It is not the same as distilled water or tap water.

Why do some people say compounded tirzepatide "burns" more than Mounjaro? The most common cause is incorrect osmolality in the compounded formulation. If the sodium chloride concentration is wrong, the solution becomes hypertonic or hypotonic, causing injection-site pain. Brand-name Mounjaro has tighter manufacturing controls, so osmolality is more consistent.

Can I take Mounjaro if I have a sulfite allergy? Yes. Mounjaro does not contain sulfites. Sodium chloride and sodium phosphate are not sulfites. Sulfite allergies (common in people with asthma) are not a contraindication to Mounjaro.

Does Mounjaro contain gluten, soy, or dairy? No. The formulation contains no gluten, soy, dairy, egg, shellfish, nuts, or other common food allergens.

What is the purpose of hydrochloric acid and sodium hydroxide in Mounjaro? They are used during manufacturing to adjust the final pH to 7.0 to 8.0. They are not present in fixed amounts. Only trace residual amounts remain in the final product after pH adjustment is complete.

Sources

1. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Eli Lilly and Company. Mounjaro (tirzepatide) injection prescribing information. 2022.
4. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018.
5. Thomas MK et al. Tirzepatide, a dual GIP and GLP-1 receptor agonist, improves markers of beta-cell function and insulin sensitivity in type 2 diabetes. Journal of Clinical Endocrinology & Metabolism. 2021.
6. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Care. 2020.
7. U.S. Food and Drug Administration. Inactive ingredient database. 2025.
8. U.S. Pharmacopeia. General chapter on water for injection. USP 43-NF 38. 2020.
9. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
10. Manning S et al. Stability of peptide and protein pharmaceuticals. Pharmaceutical Research. 2010.
11. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics. 1999.
12. Carpenter JF et al. Rational design of stable lyophilized protein formulations: theory and practice. Pharmaceutical Biotechnology. 2002.
13. Shire SJ et al. Challenges in the development of high protein concentration formulations. Journal of Pharmaceutical Sciences. 2004.
14. Frokjaer S et al. Protein drug stability: a formulation challenge. Nature Reviews Drug Discovery. 2005.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro is a registered trademark of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.